Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

Phase 2 Completed 75 enrolled GlaxoSmithKline

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.

Timeline

Start: 2006-12
Primary completion: 2009-12
Completion: 2009-12

Publications

de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):751-9. doi: 10.1007/s10637-012-9885-8. Epub 2012 Oct 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lapatinib	Small molecule	1000 mg	Oral
Subject	Lapatinib	Small molecule	1500 mg	Oral
Subject	Pazopanib	Small molecule	400 mg	Oral
Subject	Pazopanib	Small molecule	800 mg	Oral

Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications